Testing HYP-2090PTSA in patients with advanced solid tumors and KRAS mutations

An Open-label, Multi-center, Multi-cohort, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HYP-2090PTSA in Patients With Advanced Solidt Tumors Harboring KRAS Mutation

This study is testing a new drug called HYP-2090PTSA to see if it can safely help people with advanced solid tumors that have a KRAS mutation.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 257 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd (Industry-sponsored)
• Drugs / interventions: chemotherapy
• Locations: 6 sites (Fuzhou, Fujian and 5 other locations)
• Trial ID: NCT06243354 on ClinicalTrials.gov

What this trial studies

This multicenter, open-label phase 1/2 study evaluates the safety, tolerability, and pharmacokinetics of HYP-2090PTSA in patients with advanced solid tumors that have a KRAS mutation. The study consists of two parts: a dose escalation phase to determine the recommended phase 2 dose (RP2D) and a dose expansion phase to further explore the efficacy and safety of the drug at the RP2D in patients with specific KRAS p.G12C mutations. Participants will be monitored for measurable lesions and overall health status throughout the trial.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with confirmed advanced solid tumors and at least one measurable lesion.

Not a fit: Patients who have recently undergone major surgical or interventional treatments or have received anti-tumor therapies within the last four weeks may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors harboring KRAS mutations.

How similar studies have performed: While this approach is novel in its specific targeting of KRAS mutations, similar studies have shown promise in targeting other mutations in solid tumors.

Eligibility criteria

Inclusion Criteria:

* A written informed consent should be signed by a subject or his/her legal representative before any study-related procedures are performed;
* 18 Years and older;
* Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors;
* Subjects must have at least one measurable lesion as defined by RECIST v1.1;
* Eastern Cooperative Oncology Group(ECOG) performance status 0-1;
* Expected survival ≥ 3 months;
* Patients are willing to use a highly effective method of birth control during the study, and for at least 180 days after the last dose of study medication.

Exclusion Criteria:

* Patients who have received major surgical or interventional treatment within 4 weeks prior to the first dose, with the exception of tumor biopsy, puncture, etc. Patients who have received anti-tumor therapy (radiotherapy, immunologic therapy or biological therapy) within 4 weeks, prior to the first dose, or received small molecular targeted therapy, chemotherapy within 2 weeks, or received palliative radiotherapy for bone metastases within 2 weeks, or received nitrosoureas or mitomycin C within 6 weeks;
* Patients who have received live vaccines within 4 weeks prior to the first dose;
* Patients who have previously participated in clinical trials of other drugs within 4 weeks before the first dose;
* Patients with a history of central nervous system disease within 12 months prior to enrollment, such as seizures, cerebral vascular embolism/hemorrhage, paralysis, aphasia, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychiatric disease, or any autoimmune disease with involvement of the central nervous system;
* Presence of severe pulmonary diseases such as pulmonary embolism, interstitial lung disease at screening;
* Patients who have previously received allogeneic tissue/solid organ transplantation;
* Patients with active infection;
* Patients who are positive for human immunodeficiency virus (HIV) (HIV1/2 antibody), positive treponema pallidum antibody (positive treponema pallidum antibody is required to undergo a confirmatory test, and those with negative confirmatory test can be enrolled), active chronic hepatitis B (HBsAg positive and HBV DNA \> 500 IU/mL) or active hepatitis C (HCV antibody positive and HCV-RNA \> lower limit of detection by the research center);
* Female subjects who are lactating or have a positive blood/urine pregnancy result during the screening period;
* Any other condition of the subject (e.g., mental, geographical, or medical condition) that does not allow him or her to comply with the study and follow-up procedures, or other conditions that, in the judgment of the investigator, the subject is not suitable for inclusion in this study.

Where this trial is running

Fuzhou, Fujian and 5 other locations

• Fujian Provincial Cancer Hospital — Fuzhou, Fujian, China (Recruiting)
• Hunan Provincial Cancer Hospital — Changsha, Hunan, China (Not_yet_recruiting)
• The first Hospital of China Medical University — Shenyang, Liaoning, China (Not_yet_recruiting)
• Shandong Provincial Cancer Hospital — Jinan, Shandong, China (Not_yet_recruiting)
• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
• West China Hospital of Sichuan University — Chengdu, Sichuan, China (Recruiting)

Study contacts

• Study coordinator: Kai Chang

Conditions Safety; Tolerability; Efficacy